Business Description
Vertex Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US92532F1003
Compare
Compare
Traded in other countries / regions
VRTX.AustriaVRTX34.BrazilVX1.GermanyVRTX.MexicoVRTX.Switzerland0QZU.UKVRTX.USA IPO Date
1991-07-31Description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 13.2 | |||||
| Equity-to-Asset | 0.76 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | 0.18 | |||||
| Interest Coverage | 86.83 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 13.61 | |||||
| Beneish M-Score | -2.21 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 29.2 | |||||
| 3-Year EBITDA Growth Rate | 42 | |||||
| 3-Year EPS without NRI Growth Rate | 41.7 | |||||
| 3-Year FCF Growth Rate | 38.3 | |||||
| 3-Year Book Growth Rate | 32.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 44.37 | |||||
| Future 3-5Y Total Revenue Growth Rate | 9.28 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 15.84 | |||||
| 9-Day RSI | 29.81 | |||||
| 14-Day RSI | 40.54 | |||||
| 6-1 Month Momentum % | 3.3 | |||||
| 12-1 Month Momentum % | 19.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.28 | |||||
| Quick Ratio | 4.11 | |||||
| Cash Ratio | 3.44 | |||||
| Days Inventory | 138.56 | |||||
| Days Sales Outstanding | 55.5 | |||||
| Days Payable | 74.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.3 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 88.04 | |||||
| Operating Margin % | 48.37 | |||||
| Net Margin % | 35.4 | |||||
| ROE % | 25.38 | |||||
| ROA % | 19.48 | |||||
| ROIC % | 70.32 | |||||
| ROC (Joel Greenblatt) % | 292.27 | |||||
| ROCE % | 29.91 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 26.27 | |||||
| Forward PE Ratio | 23.36 | |||||
| PE Ratio without NRI | 26.27 | |||||
| Shiller PE Ratio | 72 | |||||
| Price-to-Owner-Earnings | 25.21 | |||||
| PEG Ratio | 0.28 | |||||
| PS Ratio | 9.31 | |||||
| PB Ratio | 5.89 | |||||
| Price-to-Tangible-Book | 6.67 | |||||
| Price-to-Free-Cash-Flow | 22.03 | |||||
| Price-to-Operating-Cash-Flow | 21.03 | |||||
| EV-to-EBIT | 17.86 | |||||
| EV-to-Forward-EBIT | 16.1 | |||||
| EV-to-EBITDA | 17.24 | |||||
| EV-to-Forward-EBITDA | 15.25 | |||||
| EV-to-Revenue | 8.18 | |||||
| EV-to-Forward-Revenue | 7.74 | |||||
| EV-to-FCF | 19.37 | |||||
| Price-to-Projected-FCF | 1.97 | |||||
| Price-to-Median-PS-Value | 0.63 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.05 | |||||
| Price-to-Graham-Number | 2.79 | |||||
| Price-to-Net-Current-Asset-Value | 10.09 | |||||
| Price-to-Net-Cash | 14.47 | |||||
| Earnings Yield (Greenblatt) % | 5.6 | |||||
| Forward Rate of Return (Yacktman) % | 22.85 |
Balance Sheet Breakdown
Cashflow Statement Breakdown
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VRTX
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Vertex Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 9,208 | ||
| EPS (TTM) ($) | 12.56 | ||
| Beta | 0.49 | ||
| Volatility % | 23.48 | ||
| 14-Day RSI | 40.54 | ||
| 14-Day ATR ($) | 6.802823 | ||
| 20-Day SMA ($) | 342.7475 | ||
| 12-1 Month Momentum % | 19.9 | ||
| 52-Week Range ($) | 243.17 - 354.46 | ||
| Shares Outstanding (Mil) | 257.55 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vertex Pharmaceuticals Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vertex Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Vertex Pharmaceuticals Inc Frequently Asked Questions
What is Vertex Pharmaceuticals Inc(VRTX)'s stock price today?
The current price of VRTX is $329.99. The 52 week high of VRTX is $354.46 and 52 week low is $243.17.
When is next earnings date of Vertex Pharmaceuticals Inc(VRTX)?
The next earnings date of Vertex Pharmaceuticals Inc(VRTX) is 2023-08-04 Est..
Does Vertex Pharmaceuticals Inc(VRTX) pay dividends? If so, how much?
Vertex Pharmaceuticals Inc(VRTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
